多发性骨髓瘤
医学
微小残留病
临床实习
疾病负担
骨髓
肿瘤科
疾病
疾病负担
重症监护医学
内科学
物理疗法
作者
Matthew Ho,Taxiarchis Kourelis
出处
期刊:Hematology
[American Society of Hematology]
日期:2022-12-09
卷期号:2022 (1): 356-362
被引量:2
标识
DOI:10.1182/hematology.2022000348
摘要
Novel therapies in multiple myeloma (MM) have increased the rates of conventional complete remission (CR) in patients. However, patients in CR can have highly heterogeneous outcomes. Novel and more sensitive methods of assessing residual disease burden after therapy will help prognosticate this group better and, ideally, allow individualized therapy adjustments based on response depth in the future. Here, we review novel bone marrow, peripheral blood, and imaging methods for assessing myeloma burden and discuss the opportunities and limitations of incorporating these in everyday clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI